Molecular profiling is essential before selecting systemic treatment for advanced non-small cell lung cancer. Specific activating alterations can identify patients who are likely to benefit from targeted therapy. Reference: New England Journal of Medicine. (Scroll down to answer the question) ##Disclaimer## The content provided on Docplexus is intended for educational purposes only.

While we strive to ensure its accuracy, we make no explicit or implied warranties about the information's suitability, reliability, or adequacy, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas, or service, including content from our industry partners. We do not associate with the views of any individual, community, organization, industry partner, or political party. Unauthorized use, reproduction, or distribution of the content outside the platform…